ASXL1 and neoplasm: In the chemotherapy arm, early progression was associated with liver, adrenal gland or brain metastasis, or greater number of metastatic sites overall, higher SLD or tumor mutations in SMARCA, ASXL1 or CDKN2A (P < 0.05).